Could a Generic Zocor ''Hurt'' The Statin Market?

Last week, I told you about Pfizer dodging a bullet when its cash cow, Lipitor, was protected from the generic drug market for five more years by a federal judge. An astute look at the mega-pharmaceutical landscape in yesterday''s Chicago Tribune shows how the soon-to-be-generic status of another worthless statin drug -- Zocor -- will be a boon to the conventional drug paradigm at the end of the day.

With Zocor moving to generic status in June, this statin will cost close to half as much ($2 a pill) at the retail level. And, because one statin isn''t any better -- if not worse -- than any other, health care plans as well as pharmacies will likely be encouraging patients to use the cheaper generic instead.

Another advantage for a generic Zocor product: The looming disaster that is the Medicare drug benefit package.

Truth is, you can enjoy the same benefits you receive from a statin drug -- generic or not -- without taking one by making simple lifestyle changes which include modifying your eating habits based on your body''s unique nutritional type.

Chicago Tribune December 29, 2005 Registration Required

Post your comment
Click Here and be the first to comment on this article